Fri, Feb 27, 2015, 6:36 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

ImmunoGen, Inc. Message Board

  • bioimmunomabman bioimmunomabman Mar 11, 2013 3:59 PM Flag


    Anyone here following this one? Looks interesting, antibiotic for strong, hard to treat bacteria stuff. In the firs phase III their results were similar/non-inferior to the established market leader with lower side effects (sound familiar). The goal is lower side effects, fewer days in the hospital. Results of a second phase III are expected this month. The management team looks strong on paper. The stock was relatively unknown until SA article last week, I had never heard of the company. It rose about $1 fast, but still has a modest market cap of $250MM. Because of the risk, I am playing it through a long call spread, long the lower price option, short the $higher price option. It's worth a look. All IMO, not advice.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Just bought in on your advice, so you better hope it goes up or I will have to kill you :-)

      [Seriously, I did check it out on your lead, and I liked it. Hope we both profit]

      I would note that non-inferiority trials are the norm for antibiotics. The reason is that in the overall setting these basically "work" and it is hard to do better than the existing anti-b overall. So one tries to do the same while improving resistance,AEs, etc.

      I do thing the improved dosing is a real win. Compliance truly is one of (if not the main) cause of failure here. Obviously once a day for a week is more likely to be complied with than twice daily for 12 days (or whatever the exact numbers are).

      I am a bit skeptical on the platet issue (the numbers are just so small). I think all you can really say is that it is no worse than linezolid. The other AEs are minor, but again might lead to slightly better compliance.

      Good luck!

    • Heavily manipulated, but drug seems fine. Going up again with anticipated news on ph3 results this month, then will be dumped again to low 5s or lower.

    • Judging by the state of affairs with existing anti-biotics, this might be worth looking into.

7.60-0.19(-2.44%)Feb 27 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.